Cardiology
CHA₂DS₂-VA Score
Stroke risk in AF (2024, sex removed).
Education and reference only. Not a substitute for clinical judgement, local policy or product labelling. Always verify before clinical use. Values are calculated in your browser and never stored.
Background
CHA₂DS₂-VA estimates the risk of stroke and systemic embolism in non-valvular atrial fibrillation (AF) and guides decisions about anticoagulation. It is the variant introduced in the 2024 ESC AF guideline, which removed the female sex category (the 'Sc') from the older CHA₂DS₂-VASc score to give a single, sex-independent score. Points are: Congestive heart failure or left-ventricular dysfunction (1), Hypertension (1), Age ≥75 (2), Diabetes (1), prior Stroke/TIA/thromboembolism (2), Vascular disease (1) and Age 65–74 (1) — a maximum of 8.
Interpreting the result
Risk rises with the score. A score of 0 is low risk and anticoagulation is not generally recommended; a score of 1 is an intermediate group in whom anticoagulation should be considered after weighing individual factors; and a score of 2 or more warrants anticoagulation unless there is a strong contraindication. Removing the sex category simplifies the decision so that men and women are assessed on the same threshold. The score guides whether to anticoagulate but does not choose the agent.
Advice
The 2024 ESC AF guideline uses CHA₂DS₂-VA (no sex category). Weigh against bleeding risk; do not withhold where stroke risk warrants treatment.
Worked example
A 78-year-old with hypertension and type 2 diabetes scores Age ≥75 (2) + Hypertension (1) + Diabetes (1) = 4. This is a high-risk group, so anticoagulation is recommended unless contraindicated, after assessing and addressing modifiable bleeding risk.
Pearls / pitfalls
- CHA₂DS₂-VA drops the sex point compared with CHA₂DS₂-VASc, so a woman whose only previous point was sex is now scored as low risk.
- Always pair it with a bleeding-risk assessment and correct modifiable bleeding factors — a high bleeding risk is a reason to manage risk, not to reflexively withhold anticoagulation.
- 'Non-valvular' is key: mechanical heart valves or moderate-to-severe mitral stenosis require anticoagulation regardless of the score.
- The score supports a shared decision; it does not replace clinical judgement or patient preference.
Evidence & validation
The sex-less CHA₂DS₂-VA score is recommended in the 2024 ESC guidelines for the management of atrial fibrillation (Van Gelder et al.), reflecting evidence that female sex acts as a risk modifier rather than an independent driver of stroke risk.
Frequently asked questions
How is CHA₂DS₂-VA different from CHA₂DS₂-VASc?
CHA₂DS₂-VA removes the female sex category, giving a maximum of 8 instead of 9. The 2024 ESC guideline adopted it because female sex is now treated as a risk modifier rather than an independent risk factor.
What score means anticoagulation is recommended?
A score of 2 or more generally warrants anticoagulation unless contraindicated. A score of 1 is a consider category, and a score of 0 is low risk where anticoagulation is not routinely offered.
Does this score apply to women differently?
No — that is the point of the change. By removing the sex category, men and women are assessed against the same thresholds.
Does CHA₂DS₂-VA estimate bleeding risk?
No. It only estimates stroke and thromboembolism risk. Bleeding risk is assessed separately, and modifiable bleeding factors should be addressed.
Can I use it in valvular AF?
No. People with mechanical valves or moderate-to-severe mitral stenosis need anticoagulation irrespective of the score.
References
- Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2024;45(36):3314–3414.
- Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation (CHA₂DS₂-VASc). Chest. 2010;137(2):263–272.
Related calculators
Need a calculator we don't have — or a custom tool?
We build evidence-led clinical calculators, dashboards and reference tools for teams.